An unusual study presented at the European Society of Cardiology (ESC) congress in Madrid today has found that treating heart ...

The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, ...

This includes exploring the use of complement-mediators as combination therapies, discovering innovative indications where ...

Gadoquatrane is being assessed by the US regulator for contrast-enhanced MRI scans of the central nervous system and other ...

Nykode will boost its spending on its third major platform – designed to induce tolerance in autoimmune diseases – but a partnership with Regeneron spanning off-the-shelf cancer immunotherapies and ...

While economic evaluations remain the purview of national bodies, the JCA now mirrors the centralised approach of the ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight with type 2 diabetes, showed that the ...

Pharma commercialisation services provider EVERSANA (pharmaphorum's parent company) has acquired Waltz Health, a Chicago ...

Current therapies for gMG include AstraZeneca/Alexion's complement C5 inhibitor Ultomiris (ravulizumab), which needs to be ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 ...